Find Atosiban manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

NDC API

NDC API

0

VMF

NDC API

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Canada

Canada

0

Australia

Australia

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

4RELATED EXCIPIENT COMPANIES

8EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Tractocile, 90779-69-4, Antocin, Antocin ii, Tractocil, Rwj 22164
Molecular Formula
C43H67N11O12S2
Molecular Weight
994.2  g/mol
InChI Key
VWXRQYYUEIYXCZ-OBIMUBPZSA-N
FDA UNII
081D12SI0Z

Atosiban
Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in the literature in 1985. Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women.
1 2D Structure

Atosiban

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-N-[(2S)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16R)-7-(2-amino-2-oxoethyl)-13-[(2S)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-10-[(1R)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
2.1.2 InChI
InChI=1S/C43H67N11O12S2/c1-5-23(3)35-41(63)53-36(24(4)55)42(64)50-29(20-32(45)56)38(60)51-30(43(65)54-17-8-10-31(54)40(62)49-27(9-7-16-44)37(59)47-21-33(46)57)22-68-67-18-15-34(58)48-28(39(61)52-35)19-25-11-13-26(14-12-25)66-6-2/h11-14,23-24,27-31,35-36,55H,5-10,15-22,44H2,1-4H3,(H2,45,56)(H2,46,57)(H,47,59)(H,48,58)(H,49,62)(H,50,64)(H,51,60)(H,52,61)(H,53,63)/t23-,24+,27-,28+,29-,30-,31-,35-,36-/m0/s1
2.1.3 InChI Key
VWXRQYYUEIYXCZ-OBIMUBPZSA-N
2.1.4 Canonical SMILES
CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCCC(=O)NC(C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCCC3C(=O)NC(CCCN)C(=O)NCC(=O)N)CC(=O)N)C(C)O
2.1.5 Isomeric SMILES
CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSCCC(=O)N[C@@H](C(=O)N1)CC2=CC=C(C=C2)OCC)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(=O)N)CC(=O)N)[C@@H](C)O
2.2 Other Identifiers
2.2.1 UNII
081D12SI0Z
2.3 Synonyms
2.3.1 MeSH Synonyms

1. (mpa(1),d-tyr(et)2,thr(4),orn(8))oxytocin

2. (mpa(1)-d-tyr(et)(2)-thr(4)-orn(8))-oxytocin

3. 1-deamino-2-tyr(oet)-4-thr-8-orn-oxytocin

4. Orf 22164

5. Orf-22164

6. Oxytocin, 1-deamino-(o-et-tyr)(2)-thr(4)-orn(8)-

7. Oxytocin, 1-deamino-o-ethyltyrosyl(2)-threonyl(4)-ornithine(8)-

8. Rwj 22164

9. Rwj-22164

2.3.2 Depositor-Supplied Synonyms

1. Tractocile

2. 90779-69-4

3. Antocin

4. Antocin Ii

5. Tractocil

6. Rwj 22164

7. Orf 22164

8. Antocile

9. Orf-22164

10. Rwj-22164

11. Cap-476

12. Chembl382301

13. F-314

14. Cap-449

15. Cap-581

16. 081d12si0z

17. Dtvt

18. (2s)-n-[(2s)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4r,7s,10s,13s,16r)-7-(2-amino-2-oxoethyl)-13-[(2s)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-10-[(1r)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide

19. Ncgc00165718-01

20. Rw-22164

21. 1-(3-mercaptopropionic Acid)-2-(3-(p-ethoxyphenyl)-d-alanine)-4-l-threonine-8-l-ornithineoxytocin

22. Atosibanum

23. Oxytocin, 1-(3-mercaptopropanoic Acid)-2-(o-ethyl-d-tyrosine)-4-l-threonine-8-l-ornithine-

24. Atosibanum [inn-latin]

25. 1-deamino-2d-tyr-(oet)-4-thr-8-orn-oxytocin

26. Atosiban [usan:inn:ban]

27. Unii-081d12si0z

28. 1-(3-mercaptopropanoic Acid)-2-(o-ethyl-d-tyrosine)-4-l-threonine-8-l-ornithineoxytocin

29. Detvt

30. Atosiban [usan]

31. Atosiban [inn]

32. Atosiban [mi]

33. Atosiban [mart.]

34. Atosiban [who-dd]

35. Dsstox_cid_28917

36. Dsstox_rid_83184

37. Dsstox_gsid_48991

38. Schembl34316

39. D[d-tyr(et)2,thr4]ovt

40. Chembl_332615

41. Gtpl2213

42. Atosiban, >=98% (hplc)

43. Dtxsid8048991

44. Cap-440

45. Chebi:135899

46. Orf22164

47. Tox21_113474

48. Bdbm50177595

49. D[d-tyr(et)2,thr4,orn8]vasotocin

50. Akos015994643

51. Zinc169362009

52. Ccg-270604

53. Db09059

54. Hs-2003

55. Ncgc00165718-02

56. Cas-90779-69-4

57. Ft-0652583

58. 79a694

59. A14334

60. C77085

61. (2s)-5-amino-2-{[(2s)-1-{[(4r,7s,10s,13s,16r)-13-[(2s)-butan-2-yl]-7-(carbamoylmethyl)-16-[(4-ethoxyphenyl)methyl]-10-[(1r)-1-hydroxyethyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}pyrrolidin-2-yl]formamido}-n-(carbamoylmethyl)pentanamide

62. (2s)-n-[(2s)-5-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxopentan-2-yl]-1-[(4r,7s,10s,13s,16r)-7-(2-amino-2-oxoethyl)-13-[(2s)-butan-2-yl]-16-[(4-ethoxyphenyl)methyl]-10-(1-hydroxyethyl)-6,9,12,15,18-pentaoxo1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide

63. Glycinamide, O-ethyl-n-(3-mercapto-1-oxopropyl)-d-tyrosyl-l-isoleucyl-l-threonyl-l-asparaginyl-l-cysteinyl-l-prolyl-l-ornithyl-, Cyclic (1->5)-disulfide

2.4 Create Date
2005-12-16
3 Chemical and Physical Properties
Molecular Weight 994.2 g/mol
Molecular Formula C43H67N11O12S2
XLogP3-1.9
Hydrogen Bond Donor Count11
Hydrogen Bond Acceptor Count15
Rotatable Bond Count18
Exact Mass993.44120896 g/mol
Monoisotopic Mass993.44120896 g/mol
Topological Polar Surface Area416 Ų
Heavy Atom Count68
Formal Charge0
Complexity1770
Isotope Atom Count0
Defined Atom Stereocenter Count9
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Atosiban is indicated for use in delaying imminent pre-term birth in pregnant adult women with: - regular uterine contractions of at least 30 s duration at a rate of at least 4 per 30 min - a cervical dilation of 1-3cm (0-3cm for nulliparas) and effacement of at least 50% - a gestational age of 24-33 weeks - a normal fetal heart rate


Tractotile is indicated to delay imminent pre-term birth in pregnant adult women with:

- regular uterine contractions of at least 30 seconds duration at a rate of 4 per 30 minutes;

- a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of 50%;

- a gestational age from 24 until 33 completed weeks;

- a normal foetal heart rate.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Atosiban reduces the frequency of uterine contractions to delay pre-term birth in adult females and induces uterine quiescence.


5.2 MeSH Pharmacological Classification

Hormone Antagonists

Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. (See all compounds classified as Hormone Antagonists.)


Tocolytic Agents

Drugs that prevent preterm labor and immature birth by suppressing uterine contractions (TOCOLYSIS). Agents used to delay premature uterine activity include magnesium sulfate, beta-mimetics, oxytocin antagonists, calcium channel inhibitors, and adrenergic beta-receptor agonists. The use of intravenous alcohol as a tocolytic is now obsolete. (See all compounds classified as Tocolytic Agents.)


5.3 ATC Code

G02CX01


G02CX01

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


G - Genito urinary system and sex hormones

G02 - Other gynecologicals

G02C - Other gynecologicals

G02CX - Other gynecologicals

G02CX01 - Atosiban


5.4 Absorption, Distribution and Excretion

Absorption

In women receiving 300 g/min by infusion for 6-12 h, average steady state concentrations of 442 ng/mL were reached within 1 h. Steady state concentrations increase proportionally to dosage.


Route of Elimination

Small amounts of atosiban are found in the urine with 50 times the amount appearing as the large fragment metabolite (des-(Orn, Gly-NH2)-[Mpa, D-Tyr(Et), Thr]-oxytocin. The amount of drug excreted in the feces is not known.


Volume of Distribution

Atosiban has a mean volume of distribution of 41.8 L. Atosiban crosses the placenta and, at a dose of 300 g/min, was found to have a 0.12 maternal/fetal concentration ratio.


Clearance

Atosiban has a mean clearance rate of 41.8 L/h.


5.5 Metabolism/Metabolites

There are two metabolites of atosiban created through the cleavage of the peptide bond between ornithine and proline which is thought to be facilitated by prior cleavage of the disulfide bridge. The larger fragment remains active as an antagonist of oxytocin receptors but is 10 times less potent than the parent molecule. At a dosage of 300 g/min the ratio of parent molecule to the main metabolite was observed to be 1.4 at the second hour and 2.8 at the end of infusion.


5.6 Biological Half-Life

Atosiban does not conform to either 1-compartment or 2-compartment kinetics. It has been determined to have an initial half life (t) of 0.21 h and a terminal half life (t) of 1.7 h.


5.7 Mechanism of Action

Atosiban is a synthetic peptide oxytocin antagonist. It resembles oxytocin with has modifications at the 1, 2, 4, and 8 positions. The N-terminus of the cysteine residue is deaminated to form 3-mercaptopropanic acid at position 1, at position 2 L-tyrosine is modified to D-tyrosine with an ethoxy group replacing the phenol , threonine replaces glutamine at postion 4, and ornithine replaces leucine at position 8. It binds to membrane bound oxytocin receptors on the myometrium and prevents oxytocin-stimulated increases in inositol triphosphate production. This ultimately prevents release of stored calcium from the sarcoplasmic reticulum and subsequent opening of voltage gated calcium channels. This shutdown of cytosolic calcium increase prevents contractions of the uterine muscle, reducing the frequency of contractions and inducing uterine quiescence. Atosiban has more recently been found to act as a biased ligand at oxytocin receptors. It acts as an antagonist of Gq coupling, explaining the inhibition of the inositol triphosphate pathway thought to be responsible for the effect on uterine contraction, but acts as an agonist of Gi coupling. This agonism produces a pro-inflammatory effect in the human amnion, activating pro-inflammatory signal tranducer NF-B. It is thought that this reduces atosiban's effectiveness compared to agents which do not produce inflammation as inflammatory mediators are known to play a role in the induction of labour.


Listed Suppliers

read-more
read-more

01

Bachem AG

Switzerland
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothBachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

Flag Switzerland
Digital Content Digital Content

Atosiban

About the Company : With more than 50 years of experience and expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology comp...

With more than 50 years of experience and expertise, Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide, providing a wide range of services. Over the years, Bachem has established itself as a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides. The company is headquartered in Switzerland and has offices in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
Bachem company banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

Flag U.S.A
Digital Content Digital Content

Atosiban

About the Company : Established in 1982, ChemWerth is a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company. ChemWerth offers cGMP-quality APIs ...

Established in 1982, ChemWerth is a US-headquartered full-service generic active pharmaceutical ingredient (API) development and supply company. ChemWerth offers cGMP-quality APIs to regulated markets worldwide and has exclusive partnerships for new product development, compliance support and secure supply chain logistics. ChemWerth has access to over 500 APIs and more than 30 manufacturing facilities in the US, Europe, India and China. ChemWerth acts as a regulatory agent for over 25 FDA-approved facilities and sells more than 100 products. It has established its presence in 38 countries. In 2020, ChemWerth filed its 500th DMF with the FDA.
Chemwerth Compnay Banner

03

LGM Pharma

U.S.A
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content

Atosiban

About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...

LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, analytical method development and testing, and commercial manufacturing. LGM Pharma offers custom API synthesis, analytical development, and regulatory services. With a network of over 300 accredited CGMP manufacturing partners, LGM provides unparalleled supply chain security. And, with over 100,000 square feet of FDA-inspected cGMP manufacturing and warehouse capacity, LGM Pharma provides a one-stop solution for solid dose, powder, semi-solid and liquid drugs.
LGM Pharma CB

04

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothRochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

Flag U.S.A
Digital Content Digital Content

Atosiban Acetate

About the Company : Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quali...

Established in 1994, Rochem is a distributor of pharmaceutical, food, nutritional and animal health ingredients to some of the largest companies in the world. It sources high-quality ingredients manufactured in China. Headquartered in the Hauppauge, New York, Rochem has 16 offices spread across the globe to cater to the needs of its customers. Rochem’s operations are fully cGMP compliant and has been audited by the USFDA as well as several multinational organizations. It also trains and audits its partners to ensure all of their technologies and systems are FDA-compliant.
Rochem

05

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content

Atosiban Acetate

About the Company : Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically...

Omgene Life Sciences Private Limited is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integrated company, we focus on developing high-quality formulations based on in-house-produced actives. With GMP-certified facilities and partnerships with contract manufacturers, we excel in formulation development for injectables, lyophilized injectables, complex generics, and oral peptide delivery systems, ensuring affordable, top-quality medicines.
Omgene Company Banner

06

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

Atosiban

About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...

Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, driving progress in the pharmaceutical industry. Leveraging our extensive experience and world-class expertise, we deliver one of the most comprehensive API portfolios in the industry with over 350 Products portfolio. Additionally, we provide tailored CDMO services, harnessing our proficiency in diverse technologies to meet our partners' unique needs, ensuring flexibility and excellence in every project.
TAPI Company Banner

07

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSpace Peptides Pharmaceutical delivers Peptide CRDMO Services at Premium Speed & Quality to transform healthcare worldwide.

Flag Switzerland
Digital Content Digital Content

Atosiban

About the Company : Space Peptides Pharmaceutical is a Swiss Chinese company headquartered in Bern, Switzerland. We specialize in offering a complete range of pharmaceutical peptide CDMO services alon...

Space Peptides Pharmaceutical is a Swiss Chinese company headquartered in Bern, Switzerland. We specialize in offering a complete range of pharmaceutical peptide CDMO services along with a diverse portfolio of generic peptide APIs. From discovery to clinical development and commercial supply, we work closely with our clients to overcome complex challenges and deliver fast, reliable, and high quality results. With advanced technologies, strict cGMP compliance, and immediately available manufacturing capacities, we are committed to providing peptides with premium speed and excellence.
Company Banner

08

Apino Pharma

China
ISPE Annual Meeting
Not Confirmed
arrow

Apino Pharma

China
arrow
ISPE Annual Meeting
Not Confirmed

Atosiban

About the Company : Apino Pharma prides itself on being an innovation-driven company that strives to continuously improve its products and services. Our dedicated innovation team collaborates with the...

Apino Pharma prides itself on being an innovation-driven company that strives to continuously improve its products and services. Our dedicated innovation team collaborates with the world’s leading research institutes and universities to develop cutting-edge formulations and technologies that bring value to our customers. We are committed to exploring new opportunities presented by technology, science and global best practices to provide quality products and services that meet and exceed our customers’ needs.
blank

09

BCN Peptides

Spain
ISPE Annual Meeting
Not Confirmed
arrow

BCN Peptides

Spain
arrow
ISPE Annual Meeting
Not Confirmed

atosiban

About the Company : BCN Peptides is a privately own company completely focused on the cGMP manufacture of Bioactive Peptides for Pharmaceutical and Veterinary applications. We are a customer oriented...

BCN Peptides is a privately own company completely focused on the cGMP manufacture of Bioactive Peptides for Pharmaceutical and Veterinary applications. We are a customer oriented organization focused on fulfilling the client’s needs at each stage of the their peptide drug development and lifecycle management. It also includes a team of dedicated and passionate scientists which help us to provide to our customer a scientific excellence in terms of synthetic peptide chemistry and analytical expertise. BCN Peptides has an excellent track record of successful inspections by Global Health Agencies (US FDA, EDQM, KFDA,…)
blank

10

ISPE Annual Meeting
Not Confirmed
arrow
arrow
ISPE Annual Meeting
Not Confirmed

Atosiban

About the Company : Founded in 2003, Hyderabad-based MSN Labs is one of the fastest-growing research-based pharmaceutical company in India. Boasting a diverse product portfolio, with multiple products...

Founded in 2003, Hyderabad-based MSN Labs is one of the fastest-growing research-based pharmaceutical company in India. Boasting a diverse product portfolio, with multiple products in the market and in the pipeline, MSN has 6 API (including Oncology) and one finished dosage facilities (one more for Oncology is being built) and an integrated R&D Center for Contract Research And Manufacturing Services (CRAMS) located in Hyderabad. MSN has won the trust of more than 250 customers across 65 countries around the globe covering the US, Europe, Latin America, Middle-East, Asia Pacific, Africa and CIS markets. Our product basket offers 100 APIs
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more
  • Development Update

Details:

Atosiban is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Premature Birth.


Lead Product(s): Atosiban,Inapplicable

Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed

Study Phase: Phase IVProduct Type: Protein

Sponsor: ZonMw | Nottingham University Hospitals NHS Trust | Amphia Hospital | St. Antonius Hospital | Deventer Ziekenhuis | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Flevoziekenhuis | Franciscus Gast

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 23, 2023

blank

01

Academisch Medisch Centrum - Universiteit van Amsterdam

Country
arrow
ISPE Annual Meeting
Not Confirmed

Academisch Medisch Centrum - Universiteit van Amsterdam

Country
arrow
ISPE Annual Meeting
Not Confirmed

Lead Product(s) : Atosiban,Inapplicable

Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

Highest Development Status : Phase IV

Partner/Sponsor/Collaborator : ZonMw | Nottingham University Hospitals NHS Trust | Amphia Hospital | St. Antonius Hospital | Deventer Ziekenhuis | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | Flevoziekenhuis | Franciscus Gast

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Atosiban is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Premature Birth.

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Inapplicable

January 23, 2023

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Thickeners and Stabilizers

read-more
read-more

Coating Systems & Additives

read-more
read-more

Taste Masking

read-more
read-more

Parenteral

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 90779-69-4 / Atosiban API manufacturers, exporters & distributors?

Atosiban manufacturers, exporters & distributors 1

53

PharmaCompass offers a list of Atosiban API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Atosiban manufacturer or Atosiban supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Atosiban manufacturer or Atosiban supplier.

PharmaCompass also assists you with knowing the Atosiban API Price utilized in the formulation of products. Atosiban API Price is not always fixed or binding as the Atosiban Price is obtained through a variety of data sources. The Atosiban Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Atosiban

Synonyms

Tractocile, 90779-69-4, Antocin, Antocin ii, Tractocil, Rwj 22164

Cas Number

90779-69-4

Unique Ingredient Identifier (UNII)

081D12SI0Z

About Atosiban

Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor. Although initial studies suggested it could be used as a nasal spray and hence would not require hospital admission, it is not used in that form. Atobisan was developed by the Swedish company Ferring Pharmaceuticals. It was first reported in the literature in 1985. Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women.

Atosiban Manufacturers

A Atosiban manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Atosiban, including repackagers and relabelers. The FDA regulates Atosiban manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Atosiban API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Atosiban manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Atosiban Suppliers

A Atosiban supplier is an individual or a company that provides Atosiban active pharmaceutical ingredient (API) or Atosiban finished formulations upon request. The Atosiban suppliers may include Atosiban API manufacturers, exporters, distributors and traders.

click here to find a list of Atosiban suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Atosiban USDMF

A Atosiban DMF (Drug Master File) is a document detailing the whole manufacturing process of Atosiban active pharmaceutical ingredient (API) in detail. Different forms of Atosiban DMFs exist exist since differing nations have different regulations, such as Atosiban USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Atosiban DMF submitted to regulatory agencies in the US is known as a USDMF. Atosiban USDMF includes data on Atosiban's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Atosiban USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Atosiban suppliers with USDMF on PharmaCompass.

Atosiban KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Atosiban Drug Master File in Korea (Atosiban KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Atosiban. The MFDS reviews the Atosiban KDMF as part of the drug registration process and uses the information provided in the Atosiban KDMF to evaluate the safety and efficacy of the drug.

After submitting a Atosiban KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Atosiban API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Atosiban suppliers with KDMF on PharmaCompass.

Atosiban WC

A Atosiban written confirmation (Atosiban WC) is an official document issued by a regulatory agency to a Atosiban manufacturer, verifying that the manufacturing facility of a Atosiban active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Atosiban APIs or Atosiban finished pharmaceutical products to another nation, regulatory agencies frequently require a Atosiban WC (written confirmation) as part of the regulatory process.

click here to find a list of Atosiban suppliers with Written Confirmation (WC) on PharmaCompass.

Atosiban GMP

Atosiban Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Atosiban GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Atosiban GMP manufacturer or Atosiban GMP API supplier for your needs.

Atosiban CoA

A Atosiban CoA (Certificate of Analysis) is a formal document that attests to Atosiban's compliance with Atosiban specifications and serves as a tool for batch-level quality control.

Atosiban CoA mostly includes findings from lab analyses of a specific batch. For each Atosiban CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Atosiban may be tested according to a variety of international standards, such as European Pharmacopoeia (Atosiban EP), Atosiban JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Atosiban USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty